PMV Pharmaceuticals Inc
PMVP
Get informed when a big investor buys or sells
+ FollowMarket Cap$80M
Close$
$0.71
52.9% downside
Current Fair Value
52.9% downsideOvervalued by 52.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $80.00 Million |
|---|---|
| Enterprise Value | $67.75 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.48 |
| Beta | 1.37 |
| Outstanding Shares | 53,386,909 |
Return
| Return on Equity | -105.20% |
|---|---|
| Return on Assets | -91.66% |
| Return on Invested Capital | -109.39% |
Valuation & Multiples
| P/E Ratio | -1.06 |
|---|---|
| PEG | 7.17 |
| Price to Sales | - |
| Price to Book Ratio | 1.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 218,900▲ 160.29% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.21%▼ 5.09% |
|---|---|
| Total Invested | $45.93M▲ 0.20% |
| Investors Holding | 65▼ 5.00% |
ESG Score
No data
About PMV Pharmaceuticals Inc
44 employeesPMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology...